Home » Stocks » LEXX

Lexaria Bioscience Corp. (LEXX)

Stock Price: $5.98 USD -0.13 (-2.13%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $6.00 +0.02 (0.33%) Feb 26, 7:54 PM
Market Cap 30.52M
Revenue (ttm) 618,117
Net Income (ttm) -3.72M
Shares Out 3.00M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $5.98
Previous Close $6.11
Change ($) -0.13
Change (%) -2.13%
Day's Open 5.89
Day's Range 5.79 - 6.08
Day's Volume 97,602
52-Week Range 3.98 - 9.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Proactive Investors - 2 weeks ago

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - Chris Bunka is a happy man. As CEO of Lexaria Bioscience (NASDAQ: LEXX) since 2006, he's battled to legitimize cannabino...

Newsfile Corp - 4 weeks ago

Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug d...

Accesswire - 1 month ago

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is plea...

Accesswire - 1 month ago

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten...

Accesswire - 1 month ago

KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin tradin...

About LEXX

Lexaria Bioscience operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

Industry
Packaged Foods
Founded
2004
CEO
Christopher A. Bunka
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
LEXX
Full Company Profile

Financial Performance

In 2020, LEXX's revenue was $384,543, an increase of 72.74% compared to the previous year's $222,610. Losses were -$4.08 million, -1.77% less than in 2019.

Financial Statements